Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Bio TherapeuticsROCO:6892 -3.71%22 PS Ratio is 20.37 as of Jul. 23, 2026, which is 27% below its 10-year median of 27.78. GuruFocus rates ROCO:6892 with a GF Score™ of 22/100 and a GF Value™ of NT$14.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, Taiwan Bio Therapeutics ranks worse than 66.24% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Taiwan Bio Therapeutics's share price is NT$25.95.
Taiwan Bio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.27. Hence, Taiwan Bio Therapeutics's PS Ratio for today is 20.37.
The historical rank and industry rank for Taiwan Bio Therapeutics's PS Ratio or its related term are showing as below:
ROCO:6892'
s PS Ratio Range Over the Past 10 Years
Min: 20.37 Med: 27.78 Max: 199.54
Current: 20.37
During the past 7 years, Taiwan Bio Therapeutics's highest PS Ratio was 199.54. The lowest was 20.37. And the median was 27.78.
ROCO:6892's PS Ratio is ranked worse than 66.24% of 930
companies
in the Biotechnology industry
Industry Median: 9.22
vs ROCO:6892: 20.37
During the past 7 years, Taiwan Bio Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 16.50% per year. The lowest was -12.70% per year. And the median was 1.90% per year.
Back to Basics: PS Ratio
Taiwan Bio Therapeutics (ROCO:6892) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6892 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Taiwan Bio Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Bio Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Taiwan Bio Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Taiwan Bio Therapeutics's Share Price of today is NT$25.95. Taiwan Bio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Taiwan Bio Therapeutics (ROCO:6892) has a PS Ratio of 20.37 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Taiwan Bio Therapeutics and its competitors. This is 27% below median its historical median of 27.78. Over the past decade, Taiwan Bio Therapeutics' PS Ratio has ranged from 20.37 to 199.54. According to the industry distribution chart, Taiwan Bio Therapeutics ranks #616 out of 930 companies in the Biotechnology industry, placing it in the top 66.2%.
Is Taiwan Bio Therapeutics' PS Ratio too high?
Taiwan Bio Therapeutics' current PS Ratio of 20.37 is 27% below median its 10-year median of 27.78. Over the past 10 years, this metric has ranged from a low of 20.37 to a high of 199.54. The Biotechnology industry median PS Ratio is 9.22. Taiwan Bio Therapeutics' value of 20.37 is 120.9% above this industry median. Based on the distribution chart, Taiwan Bio Therapeutics ranks #616 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Taiwan Bio Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Bio Therapeutics ranks #616 out of 930 companies for PS Ratio. This places Taiwan Bio Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.22. Taiwan Bio Therapeutics' value of 20.37 is 120.9% above this benchmark. Historically, Taiwan Bio Therapeutics' own PS Ratio has ranged from 20.37 to 199.54 over the past decade. While the company's 10-year median is 27.78 vs. the industry median of 9.22, Taiwan Bio Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.22, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Bio Therapeutics's current PS Ratio of 20.37 is 120.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Taiwan Bio Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Bio Therapeutics's current PS Ratio is 20.37, which is 27% below median its own 10-year median of 27.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.62, compared to a current price of NT$25.95 — trading 77.5% above its estimated fair value. The current PS Ratio is 20.37, which is 27% below median its 10-year median of 27.78 and 120.9% above the Biotechnology industry median of 9.22. Taiwan Bio Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current PS Ratio is 20.37 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued.
The current stock price of NT$25.95 is trading 77.5% above its estimated GF Value™ of NT$14.62.
GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.
Key valuation signals for ROCO:6892:
PS Ratio: 20.37 (27% below median its 10-year median of 27.78)
GF Value™: NT$14.62 vs. price of NT$25.95 (77.5% above fair value)
Industry Position: 120.9% above the Biotechnology median (#616 of 930)
No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
22GF Score
Get the complete analysis for ROCO:6892
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6892 has been successfully added to your 
